⌘K
Loading ticker…
As of 2026-08-25, Crinetics Pharmaceuticals, Inc. (CRNX) has a 3-month relative strength percentile of 98 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 85. The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 0.2%, relative volume 0.51×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CRNX is in a stage 2 uptrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 19.7% / 71.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CRNX is held by 25 ETFs as of May 2026. Top owner: VTWO at 0.10% weight, $18M notional. Top 3 carry $45M.
Held by 67 ETFs · $562M across latest filings · largest weight 2.37% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.10% | $18M | −0.03 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.08% | $18M | −0.02 pp |
| VHTVanguard Health Care ETF | 0.05% | $10M | — |
| SBIO | 2.37% | $4M | −0.15 pp |
| VTWG | 0.19% | $3M | −0.06 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $2M |
| — |
| ESML | 0.07% | $2M | −0.01 pp |
| ONEQ | 0.01% | $1M | — |
| ESGV | 0.01% | $778K | — |
| FMED | 1.65% | $675K | +0.37 pp |
Showing 10 of 25 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRNX Jan avg: -1.05% median: 4.84% win: 75% σ: 13.60% n: 4 2022-04-12 → 2026-07-31 | CRNX Feb avg: -4.13% median: -5.53% win: 50% σ: 13.17% n: 4 2022-04-12 → 2026-07-31 | CRNX Mar avg: -5.45% median: -8.95% win: 25% σ: 14.07% n: 4 2022-04-12 → 2026-07-31 | CRNX Apr avg: 2.60% median: -0.45% win: 40% σ: 12.21% n: 5 2022-04-12 → 2026-07-31 | CRNX May avg: -4.29% median: -8.33% win: 40% σ: 11.18% n: 5 2022-04-12 → 2026-07-31 | CRNX Jun avg: -1.15% median: 0.86% win: 60% σ: 11.05% n: 5 2022-04-12 → 2026-07-31 | CRNX Jul avg: 29.93% median: 5.44% win: 80% σ: 52.64% n: 5 2022-04-12 → 2026-07-31 | CRNX Aug avg: -0.57% median: -0.92% win: 25% σ: 7.08% n: 4 2022-04-12 → 2026-07-31 (current) | CRNX Sep avg: 26.61% median: 19.21% win: 75% σ: 34.27% n: 4 2022-04-12 → 2026-07-31 | CRNX Oct avg: 1.61% median: 1.46% win: 50% σ: 6.79% n: 4 2022-04-12 → 2026-07-31 | CRNX Nov avg: 3.07% median: 3.48% win: 75% σ: 4.92% n: 4 2022-04-12 → 2026-07-31 | CRNX Dec avg: 1.47% median: 2.29% win: 75% σ: 9.25% n: 4 2022-04-12 → 2026-07-31 |